Format

Send to

Choose Destination
Cytometry A. 2018 Apr;93(4):448-457. doi: 10.1002/cyto.a.23300. Epub 2018 Mar 2.

Antibody-based cell-surface proteome profiling of metastatic breast cancer primary explants and cell lines.

Author information

1
Department of Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA.
2
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
3
McGowan Institute of Regenerative Medicine, Pittsburgh, Pennsylvania.
4
Xiangya School of Medicine, Central South University, Changsha City, China.
5
Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
6
BD Biosciences, La Jolla, California.
7
Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Abstract

Flow cytometric cell surface proteomics provides a new and powerful tool to determine changes accompanying neoplastic transformation and invasion, providing clues to essential interactions with the microenvironment as well as leads for potential therapeutic targets. One of the most important advantages of flow cytometric cell surface proteomics is that it can be performed on living cells that can be sorted for further characterization and functional studies. Here, we document the surface proteome of clonogenic metastatic breast cancer (MBrCa) explants, which was strikingly similar to that of normal mesenchymal stromal cells (P = 0.017, associated with Pearson correlation coefficient) and transformed mammary epithelial cells (P = 0.022). Markers specifically upregulated on MBrCa included CD200 (Ox2), CD51/CD61 (Integrin α5/β3), CD26 (dipeptidyl peptidase-4), CD165 (c-Cbl), and CD54 (ICAM-1). Proteins progressively upregulated in a model of neoplastic transformation and invasion included CD26, CD63 (LAMP3), CD105 (Endoglin), CD107a (LAMP1), CD108 (Semaphorin 7A), CD109 (Integrin β4), CD151 (Raph blood group), and disialoganglioside G2. The proteome of the commonly used cell lines MDA-MB-231, MCF7, and BT-474 were uncorrelated with that of MBrCa (P = 1.0, 1.0, 0.9, respectively). The comparison has demonstrated the mesenchymal nature of clonogenic cells isolated by short-term culture of metastatic breast cancer, provided several leads for biomarkers and potential targets for anti-invasive therapy, including CD200, and highlighted the limitations of breast cancer cell lines for representing the cell surface biology of breast cancer.

KEYWORDS:

CD200; CD274; CD51/CD61; CD90; Lyoplate; epithelial to mesenchymal transition; metastatic breast cancer; proteomics

PMID:
29498809
DOI:
10.1002/cyto.a.23300
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center